Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant

Rhea-AI Filing Summary

Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.6900 per share and expire on July 8, 2036. The award vests in full on July 8, 2027, subject to continued service through that date. Following this grant, Stefan holds 15,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Loren Stefan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 15,000 options Exercise price: $2.6900 per share Expiration date: July 8, 2036 +2 more

5 metrics

Options granted 15,000 options Stock option grant to consultant Loren Stefan covering common stock

Exercise price $2.6900 per share Exercise price for the 15,000 stock options granted

Expiration date July 8, 2036 Expiration of stock options granted to Loren Stefan

Vesting date July 8, 2027 Options vest in full on this date subject to continued service

Holdings after transaction 15,000 options Total stock options held directly by Loren Stefan after the grant

Key Terms

Stock option (right to buy), exercise price, vest in full

3 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 2.6900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"This option shall vest in full on July 8, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 09:00 PM Accepted by SEC EDGAR 07/10/2026 - 09:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Cellectar Biosciences (CLRB) report for Loren Stefan?

Cellectar Biosciences reported that consultant Loren Stefan received a grant of 15,000 stock options to buy common stock at $2.6900 per share, expiring on July 8, 2036.

What is the vesting schedule of the new CLRB stock options granted to Loren Stefan?

The 15,000 stock options granted to consultant Loren Stefan will vest in full on July 8, 2027, subject to his continued service through that vesting date.

What is the exercise price of the Cellectar Biosciences (CLRB) options granted to Loren Stefan?

The options granted to consultant Loren Stefan have an exercise price of $2.6900 per share for 15,000 underlying shares of Cellectar Biosciences common stock.

How many CLRB options does Loren Stefan hold after this reported transaction?

After the reported grant, consultant Loren Stefan holds 15,000 stock options directly, each representing the right to purchase one share of Cellectar Biosciences common stock.

Is the Form 4/A transaction for CLRB an open-market buy or a grant?

The Form 4/A for Cellectar Biosciences shows a grant/award acquisition of 15,000 stock options to consultant Loren Stefan, not an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loren Stefan

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Consultant

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/08/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.69	07/08/2026		A		15,000		(1)	07/08/2036	Common stock	15,000	$0	15,000	D

Explanation of Responses:

1. This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

This Form 4 amendment is being filed solely to correct the exercise price of the stock option that was reported in the original Form 4 filed by the reporting person on July 8, 2026.

	/s/ Chad Kolean, attorney-in-fact for Stefan Loren	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)